Eko
Eko Health develops FDA-cleared digital stethoscopes and the SENSORA AI platform to help clinicians detect heart and lung disease.
Secondary Market Price
How Eko Measures Up
To help you manage your Eko equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Eko's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Eko Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Eko's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Eko Health is a digital health company that develops technology for detecting and monitoring heart and lung disease. The company’s products include digital stethoscopes, an AI-powered analysis platform called SENSORA, and associated software for healthcare providers. Founded in 2013 by Connor Landgraf, Jason Bellet, and Tyler Crouch, Eko has since secured multiple FDA clearances for its devices and AI algorithms. The company has sold over 650,000 devices globally and has raised more than $165 million in funding across 12 rounds.
The company is focused on expanding the use of AI-assisted auscultation in clinical settings such as primary care and emergency departments. A recent development supporting this goal is the decision by the Centers for Medicare & Medicaid Services (CMS) to establish national payment for Eko's SENSORA platform, creating a reimbursement pathway for AI-enabled cardiac disease detection. In addition to its commercial efforts, Eko is involved in global health initiatives. A study in Ghana (DAMSUN-HF) demonstrated that the company's AI-powered digital auscultation could detect a specific type of heart failure with 97% sensitivity at the point of care.
- ARTIS Ventures
- Highland Capital Partners
- Questa Capital
- NTTVC
- DigiTx Partners
- 3M Ventures
- Mayo Clinic
- Sutter Health
- Morningside Technology Ventures Limited
- Double Point Ventures
- EDBI
- LG Technology Ventures
- Co-Founder, Connor Landgraf
- Co-Founder, Jason Bellet
- Co-Founder, Tyler Crouch
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Eko worth joining?
Deciding to join a company like Eko involves assessing the potential value of its equity compensation. A platform like Prospect can help you model potential outcomes and compare the value of Eko's equity to other opportunities.
What should I do with my Eko stock?
Deciding what to do with your Eko stock requires a personalized strategy based on your financial situation and the company's outlook. Tools like Prospect can help you create a custom plan for exercising options or selling shares to maximize your returns.
Can you sell Eko stock?
As Eko is a private company, you can typically sell stock during specific liquidity events like tender offers or on secondary markets. Platforms such as Prospect offer tools to help you navigate these opportunities and track secondary market prices.
How can I find the value of my Eko stock?
Valuing stock in a private company like Eko can be complex as it isn't publicly traded. You can use a platform like Prospect, which uses predictive models and VC-grade data to help you forecast your equity's potential future value.
What is Eko's equity worth?
The ultimate worth of your Eko equity depends on the company's future success and your personal financial strategy, including tax optimization. Prospect helps you understand the potential post-tax value of your holdings by creating personalized strategies for exercising and selling.
What is Eko's stock ticker symbol?
Since Eko is a private company, it does not have a stock ticker symbol and is not traded on public stock exchanges. Ticker symbols are assigned to companies only when they become publicly listed through an IPO.
Can I buy or sell Eko stock?
As an employee, you can "buy" stock by exercising your options and can sell shares during liquidity events like tender offers or on secondary markets. A platform like Prospect provides tools and strategies for both buying and selling private company stock tax-optimally.
What is the criteria to buy or invest in Eko stock?
Investing in a private company like Eko is typically limited to institutional investors or accredited investors who meet specific income or net worth requirements. Opportunities for the general public to invest are rare before a company goes public.
